#France #Servier #Suresnes #DAY ONE #OJEMDA

Servier Completes Acquisition of Day One Biopharmaceuticals

Servier, an independent international pharmaceutical group governed by a foundation, has formally concluded its acquisition of Day One Biopharmaceuticals, a company focused on developing targeted therapies for patients with serious conditions. This strategic move, announced on April 23, 2026, marks a significant step in Servier's efforts to expand its oncology portfolio, particularly in treatments for pediatric low-grade glioma, a common form of brain tumor in children.

Key Details of the Acquisition

The acquisition, valued at approximately $2.5 billion in equity, involved a tender offer of $21.50 per share for Day One’s outstanding shares. With this acquisition, Servier not only gains the FDA-approved drug OJEMDA (tovorafenib), which is already marketed in the United States for low-grade pediatric glioma, but also enhances its pipeline with clinical candidates targeting rare cancers that have significant unmet needs.

Olivier Laureau, President of Servier, described this acquisition as a pivotal achievement in alignment with the company's ambition for 2030. It is aimed at reinforcing its leadership in oncology, particularly concerning rare cancers like pediatric low-grade glioma.

Laureau stated, "Integrating the scientific and clinical expertise of Day One will significantly bolster our group's capacity to support long-term innovation and convert scientific advancements into effective treatments for children and families affected by rare cancers."

Enhancing the Oncology Pipeline

The inclusion of Day One's robust pipeline further solidifies Servier's resources dedicated to oncology. The company is set to incorporate programs that span from early clinical stages to phase 3 trials. Along with tovorafenib, Day One's pipeline includes Emi-Le, a novel antibody-drug conjugate (ADC), and DAY301, which targets various rare cancers.

Day One has been active in the market with OJEMDA, having successfully licensed the drug's rights outside the United States to Ipsen. This ongoing partnership is expected to enhance availability and access to crucial therapies in international markets, leveraging the strengths of both companies.

Future Prospects

The acquisition of Day One is particularly timely as it opens new avenues for Servier in the evolving landscape of oncology treatments in the United States. David K. Lee, Executive Vice President of Servier Pharmaceuticals, noted, "Welcoming Day One into Servier introduces a new chapter in our expansion, allowing us to enhance our efforts in serving patients with rare cancers. Their strong scientific capabilities and a proven therapy will aid us in translating innovation into tangible benefits for patients."

The transaction underscores Servier's commitment to focused development and innovation aimed specifically at addressing the challenges faced by patients suffering from rare cancers. As the company integrates Day One’s resources and expertise, it is poised to deliver significant advancements in treatment options for this vulnerable patient population.

In summary, this acquisition represents not just a financial investment but a strategic enhancement of Servier’s capacity to deliver innovative therapies that meet critical medical needs in the field of oncology. The comprehensive integration of Day One's assets promises to foster growth and innovation, benefiting patients today and in the years to come.